MARKET

AVIR

AVIR

Atea Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.62
+0.64
+2.46%
Opening 13:03 09/16 EDT
OPEN
25.68
PREV CLOSE
25.98
HIGH
26.66
LOW
25.64
VOLUME
977.90K
TURNOVER
--
52 WEEK HIGH
94.17
52 WEEK LOW
18.72
MARKET CAP
2.11B
P/E (TTM)
67.48
1D
5D
1M
3M
1Y
5Y
Atea Pharmaceuticals to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) ("Atea"), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will part...
GlobeNewswire · 09/07 11:00
BRIEF-Atea Pharmaceuticals Announces Publication Of Data Highlighting At-752’S Potent In Vitro And In Vivo Activity Against Dengue And Other Flaviviruses
reuters.com · 08/24 14:19
Atea Pharmaceuticals Announces Publication of Data Highlighting AT-752’s Potent In Vitro and In Vivo Activity Against Dengue and Other Flaviviruses
In vitro and in vivo data demonstrate favorable safety and potency against multiple dengue virus serotypes supporting ongoing clinical development of AT-752 Dengue is the fastest-spreading mosquito-borne viral disease with an estimated 400 million infectio...
GlobeNewswire · 08/24 11:00
Read This Before Judging Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) ROE
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Simply Wall St. · 08/13 05:37
BRIEF-Atea Pharmaceuticals Provides Clinical And Corporate Update, Reports Q2 Results
reuters.com · 08/12 21:52
Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results
New Data in Healthy Volunteers Confirmed that AT-527’s Active Metabolite Achieved Target Antiviral Levels in Lungs, Key Site of COVID-19 Infection AT-527 Phase 2 Study Interim Results Showed Potent and Rapid Antiviral Activity in Hospitalized Patients; Stu...
GlobeNewswire · 08/12 20:05
Aviron raises $4.5M to Drive Gamified Rowing Experiences via their Best-in-Class Rowing Machine
COMTEX_391393863/2669/2021-08-11T10:31:26
CNW Group · 08/11 14:31
Atea Pharmaceuticals to Host Second Quarter Financial Results Conference Call on August 12, 2021
BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and audio webcast on Thursday, August 12, 2021 at 4:30 p.m. E...
GlobeNewswire · 08/05 11:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVIR. Analyze the recent business situations of Atea Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVIR stock price target is 51.00 with a high estimate of 60.00 and a low estimate of 37.00.
EPS
Institutional Holdings
Institutions: 102
Institutional Holdings: 58.30M
% Owned: 73.58%
Shares Outstanding: 79.24M
TypeInstitutionsShares
Increased
41
12.29M
New
37
2.77M
Decreased
18
7.66M
Sold Out
15
1.21M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.01%
Pharmaceuticals & Medical Research
-0.35%
Key Executives
Chairman/President/Chief Executive Officer/Founder/Director
Jean-Pierre Sommadossi
Chief Financial Officer/Executive Vice President/Secretary
Andrea Corcoran
Senior Vice President - Finance
Wayne Foster
Other
Janet Hammond
Other
Maria Horga
Other
John Vavricka
Lead Director/Independent Director
Franklin Berger
Director
Jerome Adams
Independent Director
Barbara Duncan
Independent Director
Bruno Lucidi
Independent Director
Polly Murphy
Independent Director
Bruce Polsky
No Data
About AVIR
Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of product candidates to treat coronavirus disease (COVID-19), dengue, chronic hepatitis C (HCV), and respiratory syncytial virus (RSV). Its purine nucleotide prodrug platform develops treatments for life threatening diseases caused by single stranded ribonucleic acid (ssRNA) viral infections. Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients with COVID-19. It is developing AT-752, an oral, purine nucleoside prodrug product candidate for the treatment of dengue. It is also developing AT-787 for the treatment of chronic HCV infection, including patients with decompensated cirrhosis. It is evaluating AT-889 and other candidates for the treatment of RSV.

Webull offers kinds of Atea Pharmaceuticals Inc stock information, including NASDAQ:AVIR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVIR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVIR stock methods without spending real money on the virtual paper trading platform.